Filing Flows › AbCellera Biologics (ABCL) › How it makes money
How AbCellera Biologics (ABCL) makes money
AbCellera Biologics (ABCL) made $4.0M of revenue in the second quarter 2026 (Q2 2026), -76% from a year earlier. Research fees brought in $3.9M (96%); Licensing and royalty revenue brought in $149K (4%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Research fees | $3.9M | 96.3% | -52% | -41% |
| Licensing and royalty revenue | $149K | 3.7% | -22% | -99% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $4.0M | 100.0% |
| Operating cash flow | $25.9M | 640.1% |
| Free cash flow | $23.8M | 587.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $4.0M | -76% |
| Q1 2026 | $8.3M | +96% |
| Q4 2025 | $44.9M | +788% |
| Q3 2025 | $9.0M | +38% |
| Q2 2025 | $17.1M | +133% |
| Q1 2025 | $4.2M | -58% |
| Q4 2024 | $5.0M | -45% |
From AbCellera Biologics' 10-Q filed Aug 5, 2026 (on EDGAR).
Questions
How does AbCellera Biologics make money?
AbCellera Biologics (ABCL) made $4.0M of revenue in the second quarter 2026 (Q2 2026), -76% from a year earlier. Research fees brought in $3.9M (96%); Licensing and royalty revenue brought in $149K (4%).
What is AbCellera Biologics' biggest business?
Research fees: $3.9M in the second quarter 2026, 96% of revenue, -41% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.